A detailed history of Almanack Investment Partners, Llc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Almanack Investment Partners, Llc. holds 6,316 shares of BMY stock, worth $367,780. This represents 0.05% of its overall portfolio holdings.

Number of Shares
6,316
Previous 5,715 10.52%
Holding current value
$367,780
Previous $237,000 37.55%
% of portfolio
0.05%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

BUY
$39.66 - $51.75 $23,835 - $31,101
601 Added 10.52%
6,316 $326,000
Q2 2024

Aug 09, 2024

SELL
$40.25 - $52.99 $11,632 - $15,314
-289 Reduced 4.81%
5,715 $237,000
Q1 2024

May 01, 2024

BUY
$47.98 - $54.4 $13,002 - $14,742
271 Added 4.73%
6,004 $325,000
Q3 2023

Oct 05, 2023

SELL
$57.89 - $64.73 $49,032 - $54,826
-847 Reduced 12.87%
5,733 $332,000
Q2 2023

Aug 07, 2023

SELL
$63.71 - $70.74 $11,404 - $12,662
-179 Reduced 2.65%
6,580 $420,000
Q4 2022

Feb 08, 2023

SELL
$68.48 - $81.09 $8,970 - $10,622
-131 Reduced 1.9%
6,759 $486,000
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $26 - $15,521
-202 Reduced 2.85%
6,890 $490,000
Q2 2022

Aug 12, 2022

SELL
$72.62 - $79.98 $27,450 - $30,232
-378 Reduced 5.06%
7,092 $550,000
Q1 2022

May 13, 2022

BUY
$61.48 - $73.72 $31,170 - $37,376
507 Added 7.28%
7,470 $550,000
Q3 2021

Nov 04, 2021

BUY
$59.17 - $69.31 $16,981 - $19,891
287 Added 4.3%
6,963 $415,000
Q2 2021

Aug 04, 2021

SELL
$61.91 - $67.42 $64,757 - $70,521
-1,046 Reduced 13.55%
6,676 $446,000
Q1 2021

May 11, 2021

BUY
$59.34 - $66.74 $458,223 - $515,366
7,722 New
7,722 $491,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Almanack Investment Partners, Llc. Portfolio

Follow Almanack Investment Partners, Llc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Almanack Investment Partners, Llc., based on Form 13F filings with the SEC.

News

Stay updated on Almanack Investment Partners, Llc. with notifications on news.